Therefore, we made use of the fact that we found the clinically advanced GCLC inhibitor BSO to induce lipid ROS-dependent ferroptosis in non-NE SCLC cells (Fig. 5e). This evidence concerns the gene GCLC and small cell lung carcinoma.